A Study That Will Compare the Effect of Two Drugs on Participants With Low Bone Mass and a Recent Hip Fracture
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
This study will evaluate whether teriparatide is superior to the active comparator in the
change from baseline of lumbar spine BMD (bone mineral density) in men and postmenopausal
women with low bone mass and a recent pertrochanteric hip fracture.
Phase:
Phase 4
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Calcium Etidronic Acid Risedronate Sodium Risedronic Acid Teriparatide Vitamin D